Collaboration supports Controlled Human Infection Model (CHIM) studies that help accelerate development of effective and affordable RSV vaccines NANTES, France & GENEVA–(BUSINESS WIRE)–Naobios, a Contract Development and Manufacturing Organization (CDMO) providing bioprocess development and GMP production of clinical batches of virus-based products, and SGS, the world’s leading testing, inspection and certification company, today announce their … [Read more…]

persevERA Breast Cancer study did not meet the primary objective of a statistically significant improvement in progression-free survival, but a numerical improvement was observed Giredestrant plus palbociclib was well tolerated and adverse events were consistent with the known safety profiles of each individual treatment Genentech is committed to transforming ER-positive breast cancer care, anchored by … [Read more…]

Cetaphil’s new AM/PM Serums are powered by unique Gallic-AOX Power™ Technology, a patent-pending antioxidant complex clinically designed to sync to your skin’s circadian rhythm and support skin resilience Delivers advanced antioxidant protection by day1 and accelerated repair by night, with visible results in as little as 7 days2 In global testing, Gallic Acid demonstrated 2x … [Read more…]

Significantly more patients treated with once-daily, oral Sotyktu achieved an ACR20 response compared with placebo at Week 16 in the pivotal Phase 3 POETYK PsA-1 and POETYK PsA-2 clinical trials Sotyktu is the first and only tyrosine kinase 2 (TYK2) inhibitor to be approved for this indication PRINCETON, N.J.–(BUSINESS WIRE)–$BMY #FDA—Bristol Myers Squibb (NYSE:BMY) today … [Read more…]

– Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe – The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin … [Read more…]

Peer-reviewed study in ACS Biomacromolecules demonstrates modular VHH potency, cross-variant therapeutic activity, and a newly described immune-priming mechanism; MindWalk holds first right to commercialize jointly developed intellectual property AUSTIN, Texas–(BUSINESS WIRE)–$HYFT #ai–MindWalk Holdings Corp. (NASDAQ: HYFT), a bio-native AI company, today announced B Cell Llama™, a platform for the discovery of VHH nanobodies: the single-domain … [Read more…]

DALLAS & NEW YORK & LONDON & TOKYO–(BUSINESS WIRE)–Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position … [Read more…]

PALM BEACH GARDENS, Fla.–(BUSINESS WIRE)–#ClinicalExcellence–Viper Partners, a healthcare-focused advisory firm, is pleased to announce that it served as the exclusive advisor to Vascular Specialists in its strategic partnership with CUC America, a leading healthcare services organization focused on supporting physician-led specialty platforms. Vascular Specialists is a premier vascular care provider dedicated to delivering comprehensive diagnosis … [Read more…]

OTTAWA, Ontario–(BUSINESS WIRE)–On International Women’s Day (March 8), Canadian policymakers are being warned that strict controls on oral nicotine pouches are limiting access to an innovation linked to one of the world’s sharpest declines in female smoking. The warning accompanies the release of a new report, Empowerment in a Pouch, documenting how access to tobacco-free … [Read more…]

LOUISVILLE, Ky.–(BUSINESS WIRE)–Humana Inc. (the “company”) (NYSE: HUM) announced today that it has priced a public offering of $1.0 billion in aggregate principal amount of fixed-to-fixed rate junior subordinated notes due 2056, at 100.000 percent of the principal amount (the “Junior Subordinated Notes Offering”). The Junior Subordinated Notes Offering is expected to close on March … [Read more…]